CN112831374A - 匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 - Google Patents
匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 Download PDFInfo
- Publication number
- CN112831374A CN112831374A CN202011622214.4A CN202011622214A CN112831374A CN 112831374 A CN112831374 A CN 112831374A CN 202011622214 A CN202011622214 A CN 202011622214A CN 112831374 A CN112831374 A CN 112831374A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- extraction
- purification method
- corydalis
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 107
- 238000000605 extraction Methods 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000000746 purification Methods 0.000 title claims abstract description 24
- 241000218176 Corydalis Species 0.000 title claims abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 5
- 241000475042 Stolonifera Species 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 52
- 241000620709 Corydalis ambigua Species 0.000 claims abstract description 25
- 239000003960 organic solvent Substances 0.000 claims abstract description 19
- 230000018044 dehydration Effects 0.000 claims abstract description 14
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 14
- 238000001256 steam distillation Methods 0.000 claims abstract description 10
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 8
- 239000002274 desiccant Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000010298 pulverizing process Methods 0.000 claims abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- CYIFVRUOHKNECG-UHFFFAOYSA-N tridecan-2-one Chemical compound CCCCCCCCCCCC(C)=O CYIFVRUOHKNECG-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 3
- RHVMNRHQWXIJIS-AATRIKPKSA-N 11E-Hexadecen-1-ol Chemical compound CCCC\C=C\CCCCCCCCCCO RHVMNRHQWXIJIS-AATRIKPKSA-N 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- KEVYVLWNCKMXJX-ZCNNSNEGSA-N Isophytol Natural products CC(C)CCC[C@H](C)CCC[C@@H](C)CCC[C@@](C)(O)C=C KEVYVLWNCKMXJX-ZCNNSNEGSA-N 0.000 claims description 3
- NIDGCIPAMWNKOA-WOJBJXKFSA-N Neophytadiene Natural products [C@H](CCC[C@@H](CCCC(C)C)C)(CCCC(C=C)=C)C NIDGCIPAMWNKOA-WOJBJXKFSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229930007744 linalool Natural products 0.000 claims description 3
- -1 neokamuridol Chemical compound 0.000 claims description 3
- NIDGCIPAMWNKOA-UHFFFAOYSA-N neophytadiene Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(=C)C=C NIDGCIPAMWNKOA-UHFFFAOYSA-N 0.000 claims description 3
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- RHVMNRHQWXIJIS-UHFFFAOYSA-N Z11-16:OH Natural products CCCCC=CCCCCCCCCCCO RHVMNRHQWXIJIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940095564 anhydrous calcium sulfate Drugs 0.000 claims description 2
- LTUMRKDLVGQMJU-UHFFFAOYSA-N famesylacetone Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=O LTUMRKDLVGQMJU-UHFFFAOYSA-N 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000004821 distillation Methods 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000012153 distilled water Substances 0.000 description 5
- 238000007605 air drying Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000268804 Viola diffusa Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241001256368 Clematis chinensis Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000666657 Homo sapiens Rho-related GTP-binding protein RhoQ Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100038339 Rho-related GTP-binding protein RhoQ Human genes 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/022—Refining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0007—Aliphatic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0007—Aliphatic compounds
- C11B9/0015—Aliphatic compounds containing oxygen as the only heteroatom
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/027—Recovery of volatiles by distillation or stripping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物,涉及天然产物技术领域。该提取纯化方法包括以下步骤:将匍伏堇粉碎后,加水搅拌,并进行水蒸气蒸馏3‑6h,得含挥发油水系;向含挥发油水系中加入有机溶剂进行萃取,弃去分出的水层,向含挥发油的有机溶剂中加入脱水干燥剂脱水,过滤回收有机溶剂,得到干燥纯净的挥发油。本发明首次采用水蒸气蒸馏和有机萃取技术提取纯化得到匍伏堇挥发油,提取纯化方法工艺简单、成本低,经本发明制备工艺获得的挥发油含水率低,同时经试验验证对人肝癌细胞和人乳腺癌细胞具有高细胞毒活性,适合工业化生产应用。
Description
技术领域
本发明涉及天然产物技术领域,特别是涉及一种匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物。
背景技术
匍伏堇(Viola diffusa Ging),属于堇菜科、堇菜属植物,别名蔓茎堇菜(七星莲)。以全草入药,用于肝炎,百日咳,目赤肿痛;外用治急性乳腺炎,疔疮,痈疖,带状疱疹,毒蛇咬伤,跌打损伤。主要分布在我国浙江省,生于荒坡、耕地、溪边、疏林下及路边半阴湿地。
挥发油又称精油,是一类在常温下能挥发的、可随水蒸汽蒸馏的、与水不相混的油状液体的总称。大多数挥发油具有芳香气味。挥发油是一类重要的活性成分,临床上除直接应用主要含挥发油的生药外,还可应用从中精制的挥发油,如桉叶油、薄荷油等。挥发油具有发散解表、芳香开窍、理气止痛、祛风除湿、活血化瘀、祛寒温里、清热解毒、解暑祛秽、杀虫抗菌等作用,如薄荷油用驱风健胃,当归油镇痛,柴胡油退热,土荆芥油驱肠虫等,此外,挥发油还广泛应用于香料、食品与化妆品等的生产。
目前,对于匍伏堇的研究较少,还未有关于匍伏堇挥发油提取与使用的报道。因此,随着天然产物精细化应用的逐步实施,以及为进一步的拓展匍伏堇的应用领域,有必要对匍伏堇挥发油的提取与使用开展研究。
发明内容
本发明提供一种匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物,该匍伏堇挥发油首次采用水蒸气蒸馏和有机萃取技术提取纯化得到,该提取纯化方法工艺简单、成本低,所得挥发油含水率低,且所得挥发油对HepG2和MCF-7细胞具有高细胞毒活性作用,适合于工业化生产应用。
为了解决上述技术问题,本发明提供了一种匍伏堇挥发油的提取纯化方法,包括以下步骤:
将匍伏堇粉碎后,加水搅拌,并进行水蒸气蒸馏3-6h,得含挥发油水系;
向含挥发油水系中加入有机溶剂进行萃取,弃去分出的水层,向含挥发油的有机溶剂中加入脱水干燥剂脱水,过滤回收有机溶剂,得到干燥纯净的挥发油。
上述技术方案中,在进行水蒸气蒸馏提取时,适宜的提取时间既能够保证尽可能从匍伏堇中提取出挥发油组分,又可以避免提取时间过长造成的资源浪费。本发明在实验过程中以挥发油提取率为考察指标,对水蒸气蒸馏提取的时间进行了优化,发现提取时间以3-6h为宜,例如可以为3、3.5、4、4.5、5、5.5、6h小时,这样可最大程度的将匍伏堇中的挥发油提取出来,同时避免资源的浪费。
作为优选,所加入的匍伏堇和水的质量比为1:(2~5),优选为1:3。可以理解的是,优化匍伏堇和水的质量比可确保能够将匍伏堇中的有效成分尽可能地溶于水中,为后续蒸馏提取打好基础。
作为优选,粉碎后的匍伏堇的粒径为50-100目,优选为60目。可以理解的是,匍伏堇粉粹目数的大小会影响挥发油的提取率,粉碎颗粒过大,会使水蒸汽从原料间隙流出,使得提取率降低,且浪费资源;而粉粹的粒径过小,则使得水蒸汽无法均匀透过原料,导致蒸汽从冲开的原料中逸出,同样导致提取率不高。经优选实验发现,匍伏堇粉粹的目数以50-100目为宜,可以保证较高的挥发油提取率。在一优选方案中,匍伏堇粉粹的目数为60目,相对于其他的粉碎目数取得了最优的挥发油提取率。
作为优选,所述有机溶剂为乙酸乙酯、丙烯酸乙酯、正己烷和乙醚中的至少一种;所述脱水干燥剂为无水硫酸钠或无水硫酸钙。可以理解的是,由于关于匍伏堇有效成分的研究很少,对于匍伏堇挥发油的提取更是技术上的空白,因此,如何选择提取方法以及如何选择有机溶剂是匍伏堇挥发油提取的难点所在。本发明在实验过程中对多种不同极性的有机溶剂进行了筛选,结果发现:以乙酸乙酯、丙烯酸乙酯、正己烷、乙醚作为有机溶剂,匍伏堇挥发油的提取率较优。
作为优选,所述有机溶剂为乙醚,所述脱水干燥剂为无水硫酸钠。可以理解的是,经优选实验发现,以乙醚作为有机溶剂,相较于其他的有机溶剂具有更好的挥发油提取率。
本发明还提供了一种根据上述任一项技术方案所述的提取纯化方法制备得到的匍匐茎挥发油,所述匍匐茎挥发油的化学成分主要包括:3-羟基辛烯、芳樟醇、2-十三烷酮、新臭根子草醇、新植二烯、六氢金合欢基丙酮、(E)-11-十六碳烯-1-醇和异植醇。
作为优选,所述匍匐茎挥发油对HepG2细胞和MCF-7细胞具有高细胞毒活性作用。
作为优选,所述匍匐茎挥发油对HepG2细胞和MCF-7细胞分别在IC50为22.57μg/mL和18.22μg/mL的条件下具有高细胞毒活性作用。
本发明还提供了一种抗肿瘤药物,以上述技术方案所述的匍匐茎挥发油为主要有效成分,所述细胞为HepG2细胞和/或MCF-7细胞。
与现有技术相比,本发明的优点和积极效果在于:
本发明首次采用水蒸气蒸馏和有机萃取技术提取纯化得到匍伏堇挥发油,该提取纯化方法工艺简单,成本低,制备工艺中的蒸馏水和有机溶剂能够重复利用,经本发明制备工艺获得的挥发油含水率低,同时经试验验证匍伏堇挥发油对HepG2和MCF-7细胞具有高细胞毒活性作用,适合于工业化生产应用。
具体实施方式
下面将对本发明具体实施例中的技术方案进行详细、完整的描述。显然,所描述的实施例仅仅是本发明总的技术方案的部分具体实施方式,而非全部的实施方式。基于本发明的总的构思,本领域普通技术人员所获得的所有其他实施例,都落于本发明保护的范围。
实施例1匍伏堇挥发油的提取纯化方法
S1:取400g新鲜匍伏堇洗净晾干后粉粹至粒径为60目,加入1200g蒸馏水后搅拌进行水蒸汽蒸馏,蒸馏提取时间为4-5h,得含挥发油水系;
S2:向含挥发油水系中加入乙醚进行萃取,弃去分出的水层,向含挥发油的乙醚溶液中加入无水硫酸钠脱水,过滤回收乙醚,即得到干燥纯净的挥发油,提取率为1.42%,挥发油中的含水率为0.42%。
实施例2匍伏堇挥发油的提取纯化方法
S1:取400g新鲜匍伏堇洗净晾干后粉粹至粒径为50目,加入800g蒸馏水后搅拌进行水蒸汽蒸馏,蒸馏提取时间为5-6h,得含挥发油水系;
S2:向含挥发油水系中加入乙醚进行萃取,弃去分出的水层,向含挥发油的乙醚溶液中加入无水硫酸钠脱水,过滤回收乙醚,即得到干燥纯净的挥发油,提取率为1.39%,挥发油中的含水率为0.39%。
实施例3匍伏堇挥发油的提取纯化方法
S1:取400g新鲜匍伏堇洗净晾干后粉粹至粒径为100目,加入1600g蒸馏水后搅拌进行水蒸汽蒸馏,蒸馏提取时间为3-4h,得含挥发油水系;
S2:向含挥发油水系中加入乙醚进行萃取,弃去分出的水层,向含挥发油的乙醚溶液中加入无水硫酸钠脱水,过滤回收乙醚,即得到干燥纯净的挥发油,提取率为1.37%,挥发油中的含水率为0.41%。
实施例4匍伏堇挥发油的提取纯化方法
S1:取400g新鲜匍伏堇洗净晾干后粉粹至粒径为80目,加入2000g蒸馏水后搅拌进行水蒸汽蒸馏,蒸馏提取时间为3-4h,得含挥发油水系;
S2:向含挥发油水系中加入乙醚进行萃取,弃去分出的水层,向含挥发油的乙醚溶液中加入无水硫酸钠脱水,过滤回收乙醚,即得到干燥纯净的挥发油,提取率为1.45%,挥发油中的含水率为0.38%。
实施例5匍伏堇挥发油的检测
采用GC-MS对实施例1得到的匍伏堇挥发油进行检测,具体检测条件如下:HP-5MS色谱柱(30m×0.25mm×0.25μm);载气:氦气;流速:1.2mL/min,溶剂延迟3min;升温程序:初始温度为60℃,保持1min,以8℃/min升温到200℃,保持5min,再以5℃/min升到280℃,保持2min。离子化方式:EI,70eV;离子源温度:250℃;载气:氦气;柱流速:1.2mL/min。共检测出匍伏堇挥发油中化学成分32种,具体化学成分及相对含量见表1。
表1匍伏堇挥发油化学成分
如表1所示,所述匍匐茎挥发油的化学成分主要包括3-羟基辛烯、芳樟醇、2-十三烷酮、新臭根子草醇、新植二烯、六氢金合欢基丙酮、(E)-11-十六碳烯-1-醇和异植醇,上述组分的含量占匍匐茎挥发油总含量的66.3%。
对比例1匍伏堇挥发油的提取纯化
将S1中匍伏堇粉碎的粒径调整为40目,其余操作同实施例1,制备得到挥发油,提取率为1.13%,挥发油中的含水率为0.70%。
对比例2匍伏堇挥发油的提取纯化
将S1中匍伏堇粉碎的粒径调整为120目,其余操作同实施例1,制备得到挥发油,提取率为0.91%,挥发油中的含水率为0.62%。
对比例3匍伏堇挥发油的提取纯化
将S2中“向含挥发油水系中加入乙醚进行萃取”调整为“向含挥发油水系中加入二氯甲烷进行萃取”,其余操作同实施例1,制备得到挥发油,提取率为1.23%,挥发油中的含水率为0.72%。
对比例4匍伏堇挥发油的提取纯化
将S2中“向含挥发油水系中加入乙醚进行萃取”调整为“向含挥发油水系中加入甲苯进行萃取”,其余操作同实施例1,制备得到挥发油,提取率为1.07%,挥发油中的含水率为0.69%。
实施例6匍伏堇挥发油的细胞毒性测试
1.试验细胞株和培养基
试验细胞株:HepG2(人肝癌细胞)和MCF-7(人乳腺癌细胞)细胞株。
试验用培养基:含10%新生牛血清以及青霉素、链霉素各100U/mL的RPMI1640培养基。
2.试验方法
(1)细胞培养
HepG2(人肝癌细胞)和MCF-7(人乳腺癌细胞)细胞株用含10%新生牛血清以及青霉素、链霉素各100U/mL的RPMI1640培养基置于37℃、饱和湿度、5%CO2的培养箱中培养。
(2)MTT法检测细胞活力
取对数生长期的肿瘤细胞悬浮于含10%胎牛血清以及2mM谷氨酰胺的RPMI-1640培养基中,用玻璃吸管轻轻吹打成单细胞悬液,用TC10自动细胞计数仪计数。将细胞接种于96孔培养板,细胞密度为5×103个/mL,每孔200μL。在37℃、5%CO2的培养箱预培养25h使细胞粘附后,加入预先配制的浓度分别为0.016、0.031、0.063、0.125、0.250、0.500、1和2mg/mL的挥发油溶液对肿瘤细胞进行处理。并设阴性对照及空白对照。再分别连续培养25h、48h、72h,然后用MTT法测定。每孔加入10μL 5mg/mL的MTT溶液,继续培养2h后,吸去上清液。每孔加入100μL DMSO,置微量振荡器振荡10min使结晶完全溶解,于Multiskan Ascent酶标仪在波长570nm下测定吸光度(A)值,计算细胞增殖抑制率,该测定一式三份。
细胞增殖抑制率如下计算:
细胞增殖抑制率/%=[1-OD处理组/OD对照]×100%
3、实验结果
细胞毒性以抑制50%细胞生长时所需样品浓度即(IC50值)表示,测量结果见表2。
表2匍伏堇挥发油对HepG2及MCF-7细胞毒活性
由表2可以看出,在培养72h后,在IC50值分别为22.57μg/mL和18.22μg/mL的条件下,匍伏堇挥发油对HepG2和MCF-7细胞具有显著的细胞毒性作用。并且,随着接触时间的延长,匍伏堇挥发油的细胞毒性也在增加,表明匍伏堇挥发油的作用呈时间依赖性。
Claims (9)
1.匍伏堇挥发油的提取纯化方法,其特征在于,包括以下步骤:
将匍伏堇粉碎后,加水搅拌,并进行水蒸气蒸馏3-6h,得含挥发油水系;
向含挥发油水系中加入有机溶剂进行萃取,弃去分出的水层,向含挥发油的有机溶剂中加入脱水干燥剂脱水,过滤回收有机溶剂,得到干燥纯净的挥发油。
2.根据权利要求1所述的提取纯化方法,其特征在于,所加入的匍伏堇和水的质量比为1:(2~5),优选为1:3。
3.根据权利要求1所述的提取纯化方法,其特征在于,粉碎后的匍伏堇的粒径为50-100目,优选为60目。
4.根据权利要求1所述的提取纯化方法,其特征在于,所述有机溶剂为乙酸乙酯、丙烯酸乙酯、正己烷和乙醚中的至少一种;所述脱水干燥剂为无水硫酸钠或无水硫酸钙。
5.根据权利要求4所述的提取纯化方法,其特征在于,所述有机溶剂为乙醚,所述脱水干燥剂为无水硫酸钠。
6.根据权利要求1-5任一项所述的提取纯化方法制备得到的匍匐茎挥发油,其特征在于,所述匍匐茎挥发油的化学成分主要包括:3-羟基辛烯、芳樟醇、2-十三烷酮、新臭根子草醇、新植二烯、六氢金合欢基丙酮、(E)-11-十六碳烯-1-醇和异植醇。
7.根据权利要求6所述的匍匐茎挥发油,其特征在于,所述匍匐茎挥发油对HepG2细胞和MCF-7细胞具有高细胞毒活性作用。
8.根据权利要求7所述的匍匐茎挥发油,其特征在于,所述匍匐茎挥发油对HepG2细胞和MCF-7细胞分别在IC50为22.57μg/mL和18.22μg/mL的条件下具有高细胞毒活性作用。
9.抗肿瘤药物,其特征在于,以权利要求6所述的匍匐茎挥发油为主要有效成分,所述细胞为HepG2细胞和/或MCF-7细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011622214.4A CN112831374A (zh) | 2020-12-30 | 2020-12-30 | 匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011622214.4A CN112831374A (zh) | 2020-12-30 | 2020-12-30 | 匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112831374A true CN112831374A (zh) | 2021-05-25 |
Family
ID=75924253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011622214.4A Pending CN112831374A (zh) | 2020-12-30 | 2020-12-30 | 匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112831374A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805004A (zh) * | 2022-04-13 | 2022-07-29 | 云南瑞升烟草技术(集团)有限公司 | 一种从新鲜烟叶中制备高纯度新植二烯的绿色工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109181852A (zh) * | 2018-09-18 | 2019-01-11 | 山东大学 | 一种赛葵挥发油在制备防治癌症和抑菌产品中的应用 |
-
2020
- 2020-12-30 CN CN202011622214.4A patent/CN112831374A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109181852A (zh) * | 2018-09-18 | 2019-01-11 | 山东大学 | 一种赛葵挥发油在制备防治癌症和抑菌产品中的应用 |
Non-Patent Citations (3)
Title |
---|
JIAO-JIAO DAI,等: ""Anti-hepatitis B virus activities of friedelolactones from Viola diffusa Ging"", 《PHYTOMEDICINE》 * |
刘家仁等: "β-紫罗兰酮对人乳腺癌细胞抑制作用", 《卫生研究》 * |
吕惠玲等: "3种堇菜属植物挥发油的GC-MS分析", 《中成药》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805004A (zh) * | 2022-04-13 | 2022-07-29 | 云南瑞升烟草技术(集团)有限公司 | 一种从新鲜烟叶中制备高纯度新植二烯的绿色工艺 |
CN114805004B (zh) * | 2022-04-13 | 2023-08-08 | 云南瑞升烟草技术(集团)有限公司 | 一种从新鲜烟叶中制备新植二烯的工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103494875B (zh) | 一种青钱柳提取物在制备预防和治疗白血病药物中的应用 | |
CN102552338A (zh) | 红豆杉全株无毒提取紫杉醇口服抗癌制剂及其制备方法 | |
CN112831374A (zh) | 匍伏堇挥发油、其提取纯化方法及所得抗肿瘤药物 | |
CN114874984A (zh) | 一种采用植物提取物体外诱导扩增nk细胞的方法 | |
CN108567836A (zh) | 一种从山楂皮渣中联合提取分离黄酮和多糖的方法 | |
KR102152394B1 (ko) | 땅콩새싹 추출물로부터 분리한 핵염기를 유효성분으로 포함하는 골다공증 치료, 예방, 또는 개선용 조성물 | |
CN116492385B (zh) | 一种修复皮肤的复方精油和含有其的药物组合物 | |
CN104744601A (zh) | 一种阿魏菇多糖提取与纯化的方法 | |
CN101966212A (zh) | 一种小叶丁香树皮提取物的制备方法及其用途 | |
CN106867674B (zh) | 一种豆腐菜挥发油的提取纯化和检测方法及其应用 | |
CN104447717A (zh) | 水飞蓟黄酮木脂素的去甲基衍生物及其制备方法和其用途 | |
EP1123107A1 (en) | Process for removing impurities from natural product extracts | |
US4405613A (en) | Biologically active extracts from Maytenus nemerosa (Eckl and Zeyh) Morais (Celastraceae) South Africa and method of obtaining same | |
CN104857036B (zh) | 一种圆齿野鸦椿活性物质的提取方法及产品 | |
CN106833904B (zh) | 一种錾菜挥发油的提取纯化和检测方法及其应用 | |
CN101982183A (zh) | 一种落新妇根提取物的制备方法及其抗氧化用途 | |
CN101974008A (zh) | 小八角莲中提取纯化鬼臼毒素的工艺 | |
CN112831375A (zh) | 匍伏堇挥发油、其提取纯化方法及所得抑菌剂 | |
CN106860771B (zh) | 一种天麻精制组分的制备方法及天麻精制组分和应用 | |
CN113318141B (zh) | 砂引草提取物的应用 | |
CN114366752B (zh) | 巴戟天寡糖5聚糖单体Hex5对骨肉瘤的治疗作用 | |
CN113789224B (zh) | 金毛耳草挥发油的制备及其应用 | |
CN1264841C (zh) | 喜树细胞中抗癌活性物质的制备及用于抑制癌细胞的方法 | |
CN107936001A (zh) | 芹菜素‑8‑C‑β‑D‑木糖苷及其制备方法和应用 | |
RU2356567C1 (ru) | Эфирное масло из полыни и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210525 |
|
RJ01 | Rejection of invention patent application after publication |